How should we manage a patient with a positive PPD and prior BCG vaccination?

Journal of Family Practice

Volumn 55, Issue 8, 2006, Pages 718-720

  Rowland, Kathleen ^a   Guthmann, Richard ^a   Jamieson, Barbara ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; DIAGNOSTIC AGENT; TUBERCULIN;

BCG VACCINATION; HUMAN; IMMUNOASSAY; PROTEIN PURIFICATION; REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; VALIDATION PROCESS; COHORT ANALYSIS; EVIDENCE BASED MEDICINE; IMMUNIZATION; SENSITIVITY AND SPECIFICITY; STATISTICS;

BCG VACCINE; COHORT STUDIES; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNIZATION, SECONDARY; SENSITIVITY AND SPECIFICITY; TUBERCULIN; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33750693057     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Fine P, Camelro IA, Milstien JB, Clements CJ. Issues relating to the use of BCG immunization programmes. WHO discussion document. V&B 99.23. Available at: who.int/vaccine_research/documents/en/bcg_vaccines.pdf. Accessed on July 6, 2006.
2. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57:804-809.
3. [Erratum in: Thorax 2003; 58:188.]
4. Almeida LM, Barbieri MA, Da Paixao AC, Cuevas LE. Use of purified protein derivative to assess the risk of infection in children in close contact with adults with tuberculosis in a population with high Calmette-Guérin bacillus coverage. Ped Inf Dis J 2001; 20:1061-1065.
5. Menzies, R, Vissandjee B, Amyot D. Factors associated with tuberculin reactivity among the foreign-born in Montreal. Am Rev Respir Dis 1992; 146:752-756.
6. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59-64.
7. Dewan P, Grinsdale J, Liska S, et al. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infectious Diseases 2006; 6:47. Available at: www.biomedcentral.com/1471-2334/6/ 47. Accessed on July 6, 2006.
8. US Preventative Services Task Force. Screening for tuberculosis infection, including Bacille Calmette-Guérin immunization. Guide to Clinical Preventative Services; 1996. Available at: www.ncbi.nlm.nih.gov/books/ bv.fcgi?rid= hstat3.section.10931#13112.
9. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:1376-1395.
10. Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15):49-55.